SAN FRANCISCO, March 25, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs – peptides, proteins and small molecules - today announced that the United States Patent and Trademark Office has issued US Patent 8,680,315 covering beta-eliminative linkers that release active drug from conjugates over prolonged periods.
The recently issued patent is the first issued to ProLynx. The patent is part of an intellectual property portfolio that includes 11 US patent applications and corresponding international applications.
"This patent is an important component of ProLynx's intellectual property portfolio as our beta-eliminative linkers are the foundation of our drug delivery systems involving our weekly or bi-weekly administered circulating conjugates, as well as our implantable hydrogels for even longer duration of action," said Founder and President Daniel V. Santi, M.D., Ph.D. "What differentiates our system from others is the ultra-long half-lives of drug release – weeks to months – we can achieve with our linkers". Peg Horn, Chief Operating Officer, added "We are confident our extensive patent estate will provide our products with long-term market exclusivity".
About ProLynx LLC
ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies. ProLynx is also seeking to out-license the long lasting drug conjugates in its pre-clinical product portfolio. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found online at http://www.prolynxllc.com.